Cargando…

Identification of heterogenous treatment response trajectories to anti-IL6 receptor treatment in rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory disease with fluctuating course of progression. Despite substantial improvement in treatments in recent years, treatment response is still not guaranteed. The aim of this study was to identify variation in Disease Activity Score 28 (DAS28) of RA pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blair, J. P. M., Bay-Jensen, A.-C., Tang, M. H., Frederiksen, P., Bager, C., Karsdal, M., Brunak, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434906/ https://www.ncbi.nlm.nih.gov/pubmed/32811969 http://dx.doi.org/10.1038/s41598-020-70942-x

Ejemplares similares

The activation fragment of PAR2 is elevated in serum from patients with rheumatoid arthritis and reduced in response to anti-IL6R treatment
por: Kalogera, Stefania, et al.
Publicado: (2021)

Identification of pathological RA endotypes using blood-based biomarkers reflecting tissue metabolism. A retrospective and explorative analysis of two phase III RA studies
por: Blair, J. P. M., et al.
Publicado: (2019)

Determination of Heterogeneous Proteomic and Metabolomic Response in anti-TNF and anti-IL-6 Treatment of Patients with Rheumatoid Arthritis
por: Stepanov, Alexander A., et al.
Publicado: (2023)

Serological identification of fast progressors of structural damage with rheumatoid arthritis
por: Siebuhr, Anne Sofie, et al.
Publicado: (2013)

Endotrophin is associated with chronic multimorbidity and all-cause mortality in a cohort of elderly women
por: Staunstrup, Line Mærsk, et al.
Publicado: (2021)

Heterogeneity of treatment responses in rheumatoid arthritis using group based trajectory models: secondary analysis of clinical trial data
por: Ibrahim, Fowzia, et al.
Publicado: (2023)

Neo-Epitopes—Fragments of Cartilage and Connective Tissue Degradation in Early Rheumatoid Arthritis and Unclassified Arthritis
por: Maijer, Karen I., et al.
Publicado: (2016)

Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study
por: Drobinski, Patryk J., et al.
Publicado: (2021)

Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?
por: van Baarsen, Lisa GM, et al.
Publicado: (2014)

No effect of anti-TNF-α treatment on serum IL-17 in patients with rheumatoid arthritis
por: Sikorska, Dorota, et al.
Publicado: (2018)

Circulating Protein Fragments of Cartilage and Connective Tissue Degradation Are Diagnostic and Prognostic Markers of Rheumatoid Arthritis and Ankylosing Spondylitis
por: Bay-Jensen, Anne C., et al.
Publicado: (2013)

Identification and Prediction of Fatigue Trajectories in People With Rheumatoid Arthritis
por: Pettersson, Susanne, et al.
Publicado: (2021)

IFN-β for the treatment of rheumatoid arthritis?
por: Tak, P, et al.
Publicado: (2003)

Matrix metalloproteinase-degraded type I collagen is associated with APOE/TOMM40 variants and preclinical dementia
por: Tang, Man-Hung Eric, et al.
Publicado: (2020)

Circulating levels of IL-7 in rheumatoid arthritis
por: Churchman, S, et al.
Publicado: (2007)

Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis
por: Bay-Jensen, Anne C., et al.
Publicado: (2019)

Incidence of total hip and total knee replacements from the prospective epidemiologic risk factor study: considerations for event driven clinical trial design
por: Bager, Cecilie L., et al.
Publicado: (2019)

Chrysotherapy in the Treatment of Rheumatoid Arthritis
por: Crawford, J. C. C.
Publicado: (1937)

The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis
por: Thudium, Christian S., et al.
Publicado: (2020)

Help-seeking trajectory in patients with rheumatoid arthritis
por: Pelaez, Ingris, et al.
Publicado: (2015)

Predicting treatment response to IL6R blockers in rheumatoid arthritis
por: Nouri, Bako, et al.
Publicado: (2020)

Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006)

Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008)

Biochemical markers of ongoing joint damage in rheumatoid arthritis - current and future applications, limitations and opportunities
por: Karsdal, Morten A, et al.
Publicado: (2011)

Drivers of heterogeneity in synovial fibroblasts in rheumatoid arthritis
por: Smith, Melanie H., et al.
Publicado: (2023)

Understanding Heterogeneity in Patients’ Conceptualisation of Treatment for Rheumatoid Arthritis: A Cluster Analysis
por: Hsiao, Betty, et al.
Publicado: (2023)

The effect of anti-TNF treatment on body composition and insulin resistance in patients with rheumatoid arthritis
por: van den Oever, I. A. M., et al.
Publicado: (2020)

Ultrasound Detection of Salmonella Septic Arthritis in a Rheumatoid Arthritis Patient on Anti-TNF Treatment
por: Nandagudi, Anupama C., et al.
Publicado: (2014)

Nidogen-1 Degraded by Cathepsin S can be Quantified in Serum and is Associated with Non–Small Cell Lung Cancer
por: Willumsen, Nicholas, et al.
Publicado: (2017)

Synovial Tissue Response to Treatment in Rheumatoid Arthritis
por: Vieira-Sousa, Elsa, et al.
Publicado: (2011)

The Treatment of Rheumatoid Arthritis
Publicado: (1929)

Treatment of Rheumatoid Arthritis
Publicado: (1892)

B Cells Contribute to Heterogeneity of IL-17 Producing Cells in Rheumatoid Arthritis and Healthy Controls
por: Schlegel, Paul Martin, et al.
Publicado: (2013)

Differences in trajectory of disease activity according to biologic and targeted synthetic disease-modifying anti-rheumatic drug treatment in patients with rheumatoid arthritis
por: Koo, Bon San, et al.
Publicado: (2022)

Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis
por: O'Neill, Francis, et al.
Publicado: (2017)

IL-15 and its role in rheumatoid arthritis
por: Kurowska-Stolarska, M, et al.
Publicado: (2003)

Metabolic Effects of Anti-TNF-α Treatment in Rheumatoid Arthritis
por: Macáková, Kristína, et al.
Publicado: (2023)

Interferon-β for treatment of rheumatoid arthritis?
por: van Holten, Judith, et al.
Publicado: (2002)

Nitisinone Treatment Affects Biomarkers of Bone and Cartilage Remodelling in Alkaptonuria Patients
por: Genovese, Federica, et al.
Publicado: (2023)

Not all moderate disease is the same – Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity
por: Pan, Yi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qluapkrjaojlc3fbtg10caqjbv